Sparta Commercial Services (SRCO) 10-Q 21 Dec 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Oct. 31, 2020	Dec. 18, 2020
Cover [Abstract]
Entity Registrant Name	SPARTA COMMERCIAL SERVICES, INC.
Entity Central Index Key	0000318299
Document Type	10-Q
Document Period End Date	Oct. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--04-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		702,792,904
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Current Assets
Cash and cash equivalents
Accounts receivable	$ 18,722	1,420
Inventory	27,925	23,331
Other current assets	21,297	470
Total Current Assets	67,944	25,221
Property and equipment, net of accumulated depreciation and amortization of $213,262 and $212,905, respectively
Other assets	9,628	9,628
Deposits	9,000	9,000
Total assets	86,572	43,849
Current Liabilities
Bank overdraft	32,375	14,773
Accounts payable and accrued expenses	3,080,824	3,427,587
Short Term Loan	120,944
Current portion notes payable	5,038,655	4,942,324
Deferred revenue	13,380	16,254
Derivative liabilities	4,252,466	2,802,125
Total Current Liabilities	12,538,644	11,203,063
Loans payable-related parties	450,500	432,403
Total Long Term Liabilities	450,500	432,403
Total liabilities	12,989,144	11,635,466
Deficit:
Common stock, $0.001 par value; 750,000,000 shares authorized, 693,792,904 and 627,092,904 shares issued and outstanding, respectively	693,793	627,093
Common stock to be issued 121,452,845 and 84,786,511, respectively	121,453	84,787
Additional paid-in-capital	50,378,075	49,406,954
Accumulated deficit	(65,082,461)	(62,702,339)
Total deficiency in stockholders' equity	(13,870,889)	(12,565,868)
Non-controlling interest	968,317	974,251
Total Deficit	(12,902,572)	(11,591,617)
Total Liabilities and Deficit	86,572	43,849
Series A Convertible Preferred Stock [Member]
Deficit:
Preferred stock value	12,500	12,500
Series B Redeemable Preferred Stock [Member]
Deficit:
Preferred stock value
Series C Redeemable Convertible Preferred Stock [Member]
Deficit:
Preferred stock value	4,155	4,005
Series D Redeemable Convertible Preferred Stock [Member]
Deficit:
Preferred stock value	$ 1,596	$ 1,132

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Accumulated depreciation and amortization	$ 213,262	$ 212,905
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	693,792,904	627,092,904
Common stock, shares outstanding	693,792,904	627,092,904
Common stock to be issued	121,452,845	84,786,511
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares designated	35,850	35,850
Preferred stock, shares issued	125	125
Preferred stock, shares outstanding	125	125
Series B Redeemable Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	1,000	1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation and redemption value per share	$ 10,000	$ 10,000
Series C Redeemable Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	200,000	200,000
Preferred stock, shares issued	4,155	4,005
Preferred stock, shares outstanding	4,155	4,005
Preferred stock, liquidation and redemption value per share	$ 10	$ 10
Series D Redeemable Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	2,000,000	2,000,000
Preferred stock, shares issued	1,494	1,132
Preferred stock, shares outstanding	1,494	1,132
Preferred stock, liquidation and redemption value per share	$ 1	$ 1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Revenue
Total Revenue	$ 64,947	$ 85,229	$ 141,554	$ 180,017
Less Cost of goods sold	25,586	14,787	45,734	31,671
Gross profit	39,361	70,442	95,820	148,346
Operating expenses:
General and administrative	220,033	224,709	933,709	503,715
Depreciation and amortization		357		357
Total operating expenses	220,033	225,066	933,709	504,072
Loss from operations	(180,672)	(154,624)	(837,889)	(355,726)
Other (income) expense:
Other income	(750)	(1,200)	(750)	(2,293)
Forgiveness of debt		(311,127)	(63,053)	(311,127)
Financing cost	(14,695)	212,632	295,729	524,258
Amortization of debt discount		6,825		7,800
Loss (gain) in changes in fair value of derivative liability		1,682,995	1,310,307	292,697
Total other (income) expense	(15,445)	1,590,125	1,542,233	511,335
Income (loss) from continuing operations	(165,227)	(1,744,749)	(2,380,122)	(867,061)
Loss from discontinued operations
Net income (loss)	(165,227)	(1,744,749)	(2,380,122)	(867,061)
Net income attributed to non-controlling interest	(3,962)	(3,383)	(5,934)	(7,864)
Preferred dividend		(191)	(191)	(382)
Net income (loss) attributed to common stockholders	$ (169,189)	$ (1,748,323)	(2,386,247)	(875,307)
Basic and diluted loss per share:
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders	$ 0	$ 0
Loss from discontinued operations attributable to Sparta Commercial Services, Inc. common stockholders
Net loss attributable to Sparta Commercial Services, Inc. common stockholders	$ 0	$ 0
Weighted average shares outstanding	662,430,947	627,092,904
Information Technology [Member]
Revenue
Total Revenue	$ 61,834	$ 72,967	135,781	150,641
New World Health Brands [Member]
Revenue
Total Revenue	$ 3,113	$ 12,262	$ 5,773	$ 29,376

Condensed Consolidated Statem_2

Condensed Consolidated Statements Deficits (Unaudited) - USD ($)	3 Months Ended				6 Months Ended
	Oct. 31, 2020	Jul. 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Series A Preferred Stock [Member]
Balance	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500
Balance, shares	125	125	125	125	125	125
Balance	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500
Balance, shares	125	125	125	125	125	125
Series B Preferred Stock [Member]
Balance
Balance, shares
Balance
Balance, shares
Series C Preferred Stock [Member]
Balance	$ 4,145	$ 4,005	$ 3,258	$ 2,960	$ 4,005	$ 2,960
Balance, shares	4,145	4,005	3,258	2,960	4,005	2,960
Sale of preferred stock	$ 10	$ 140	$ 392	$ 206
Sale of preferred stock, shares	10	140	392	206
Shares issued for conversion of notes and interest				$ 92
Shares issued for conversion of notes and interest, shares				92
Balance	$ 4,145	$ 4,145	$ 4,695	$ 3,258	$ 4,145	$ 4,695
Balance, shares	4,145	4,145	3,650	3,258	4,145	3,650
Series D Preferred Stock [Member]
Balance	$ 1,494	$ 1,132	$ 705	$ 580	$ 1,132	$ 580
Balance, shares	1,494	1,132	705	580	1,132	580
Sale of preferred stock	$ 102
Sale of preferred stock, shares	102
Shares issued for settlement of accounts payable		$ 311
Shares issued for settlement of accounts payable, shares		311
Shares issued for conversion of subsidiary preferred		$ 51	$ 15	$ 125
Shares issued for conversion of subsidiary preferred, shares		51	15	125
Balance	$ 1,596	$ 1,494	$ 1,977	$ 705	$ 1,596	$ 1,977
Balance, shares	1,596	1,494	1,425	705	1,596	1,425
Common Stock [Member]
Balance	$ 627,093	$ 627,093	$ 627,093	$ 627,093	$ 627,093	$ 627,093
Balance, shares	627,092,904	627,092,904	627,092,904	627,092,904	627,092,904	627,092,904
Sale of common stock units	$ 66,700
Sale of common stock units, shares	66,700,000
Balance	$ 693,793	$ 627,093	$ 627,093	$ 627,093	$ 693,793	$ 627,093
Balance, shares	693,792,904	627,092,904	627,092,904	627,092,904	693,792,904	627,092,904
Common Stock to be Issued [Member]
Balance	$ 98,120	$ 84,787	$ 81,787	$ 80,787	$ 84,787	$ 80,787
Balance, shares	98,119,845	84,786,511	81,786,511	80,786,511	84,786,511	80,786,511
Sale of common stock units		$ 13,333
Sale of common stock units, shares		13,333,334
Common Stock to be issued	$ 23,333
Common Stock to be issued, shares	23,333,000
Shares issued for settlement of accounts payable				$ 1,000
Shares issued for settlement of accounts payable, shares				1,000,000
Balance	$ 121,453	$ 98,120	$ 85,787	$ 81,787	$ 121,453	$ 85,787
Balance, shares	121,452,845	98,119,845	81,786,511	81,786,511	121,452,845	81,786,511
Additional Paid-in Capital [Member]
Balance	$ 50,416,173	$ 49,406,954	$ 48,463,386	$ 48,215,855	$ 49,406,954	$ 48,215,855
Sale of preferred stock		69,860	195,608	102,794
Sale of common stock units	(38,098)	6,667
Stock based compensation		$ 464,718
Shares issued for conversion of notes and interest				45,737
Shares issued for settlement of accounts payable				99,000
Shares issued for settlement of accounts payable, shares		311,067
Options issued for settlement of accounts payable		$ 156,947
Shares issued for conversion of subsidiary preferred		(40)
Balance	50,378,075	50,416,173	49,850,093	48,463,386	50,378,075	49,850,093
Accumulated Deficit [Member]
Balance	(64,919,397)	(62,702,339)	(63,664,085)	(61,915,119)	(62,702,339)	(61,915,119)
Sale of common stock units	2,163
Preferred dividend		(191)	(191)
Net loss	(165,227)	(2,216,867)	873,016	(1,748,966)
Balance	(65,082,461)	(64,919,397)	(63,577,480)	(63,664,085)	(65,082,461)	(63,577,480)
Non-controlling Interest [Member]
Balance	976,212	974,251	964,578	961,320	974,251	961,320
Shares issued for conversion of subsidiary preferred		(11)	(15)	(125)
Net loss	(7,895)	1,972	4,481	3,383
Balance	968,317	976,212	969,044	964,578	968,317	969,044
Balance	(12,783,660)	(11,591,617)	(13,510,778)	(12,014,024)	(11,591,617)	(12,014,024)
Sale of preferred stock	112	70,000	196,000	103,000
Shares issued for financing cost
Sale of common stock units	35,765	20,000
Common Stock to be issued	23,333
Stock based compensation		464,718
Shares issued for conversion of notes and interest				45,829
Shares issued for settlement of accounts payable				100,000
Shares issued for settlement of accounts payable, shares		311,378
Options issued for settlement of accounts payable		$ 156,947
Shares issued for conversion of subsidiary preferred
Reclassification of derivative liability
Preferred dividend		(191)	(191)
Net loss	(165,227)	(2,214,895)	(1,744,749)	(1,745,583)	(2,380,122)	(867,061)
Balance	$ (12,902,572)	$ (12,783,660)	$ (12,437,472)	$ (13,510,778)	$ (12,902,572)	$ (12,437,472)

Condensed Consolidated Statem_3

Condensed Consolidated Statements Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,380,122)	$ (867,061)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		357
Stock based compensation	464,718
Gain from change in fair value of derivative liabilities	1,310,307	292,697
Amortization of debt discount		7,800
Non-cash financing cost	295,729	225,115
Forgiveness of debt	(63,053)	(311,127)
Changes in operating assets and liabilities
Accounts receivable	(17,302)	(6,453)
Inventory	(4,594)	(34,672)
Other assets	(20,827)	(9,978)
Accounts payable and accrued expenses	346,763	373,844
Deferred revenue	(2,874)	(2,063)
Net cash used in operating activities	(71,255)	(331,541)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment
Net cash (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Bank overdraft	17,602	(11,496)
Proceeds from sale of stock	90,000	299,000
Proceeds from notes payable	130,944	50,000
Payments on notes payable	(500)	(5,500)
Proceeds from PPP loan	120,944
Proceeds from related party notes	18,097
Payments on related party notes	(305,832)
Net cash provided by financing activities	71,255	332,004
Cash flows from discontinued operations:
Cash used in operating activities of discontinued operations
Net cash flow from discontinued operation
Net (decrease) increase in cash		463
Cash and cash equivalents, beginning of period		13
Cash and cash equivalents , end of period		476
Cash paid for:
Interest		249
Income taxes		$ 700

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows. Business Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation serving three markets. Sparta is a technology company that develops, markets and manages business mobile application (mobile apps) for smartphones and tablets. The Company also owns and manages websites which sell on-demand motorcycle, recreational vehicle, power-sport vehicle and truck title history reports for consumers, retail dealers, auction houses, insurance companies and banks/finance companies. Notwithstanding our discontinuance of consumer loans and leases, since 2007, we have offered, on a pass through basis, an equipment-leasing finance product for local and state agencies throughout the country seeking an alternative and economical way to finance their essential equipment needs, including police motorcycles and cruisers, buses and EMS equipment. Our historic customers can be viewed at https://www.spartamunicipal.com/clients Our roots are in the Powersports industry and our original focus was providing consumer leasing and retail installment contracts as well as municipal financing to the powersports, recreational vehicle, and automobile industries. Presently, through our subsidiary, iMobile Solutions, Inc. (“IMS”), we offer mobile application development, sales, marketing and support, and Vehicle Title History Reports. Our mobile application (mobile app) offerings have broadened our base beyond vehicle dealers to a wide range of businesses including, but not limited to, racetracks, private clubs, country clubs, restaurants and grocery stores. Our clients can be seen at https://imobileapp.com/app-gallery/ The Company also designs, launches, maintains, and hosts websites for businesses. We provide specific, tailored action plans for our clients’ websites that include services such as eCommerce, CRM (Customer Relationship Management) development and integration, ordering system creation and integration, SEO (search engine optimization), social media marketing, and online reviews to improve their presence online. In addition, we offer text messaging services which are vital for businesses’ marketing, retention and loyalty strategies. Our text messaging platform allows our clients to easily manage, schedule, and analyze text message performance. Our vehicle history reports, which can be found on Kelly Blue Book, AutoTrader, AllState Insurance, as well as on various dealership websites, include Cyclechex (Motorcycle History Reports at www.cyclechex.com www.rvchecks.com www.carvinreport.com www.truckchex.com New World Health Brands, Inc. (NWHB) was formed in April 2019 as a subsidiary and new business line of Sparta Commercial Services, Inc. While anticipating, and with the passing of the 2018 Farm Bill, which resulted in the removal of hemp (CBD) from Schedule 1 of the Controlled Substances Act. Sparta’s management recognized a substantial potential business opportunity in the rapidly expanding Hemp-CBD (Cannabinol) market in the United States. During 2019-2020, management sourced, developed and tested 5 CBD product categories totaling 31 products, procured product packaging, labeling, implemented fulfillment and launched an on-line B to C website, www.newworldhealthcbd.co Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of October 31, 2020 and for the three month periods ended October 31, 2020 and 2019 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2020 as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission. The results of operations for the three months ended October 31, 2020 are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2020. The condensed consolidated balance sheet as of April 30, 2020 contained herein has been derived from the audited consolidated financial statements as of April 30, 2020, but do not include all disclosures required by the U.S. GAAP. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit. Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in United States of America which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the reported period. Accordingly, actual results could differ from those estimates. Included in these estimates are assumptions about collection of accounts receivable, useful life of property and equipment, beneficial conversion feature of convertible notes payable, deferred income tax asset valuation allowances, and valuation of derivative liabilities Revenue Recognition During the first quarter of 2018, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606), using the cumulative-effect method. The new standard requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption did not have an impact in our consolidated financial statements, other than the enhancement of our disclosures related to our revenue-generating activities. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions. Revenues from mobile app products and New World Health products are generally recognized upon delivery. Revenues from history reports are generally recognized upon delivery / download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery. Cash Equivalents For the purpose of the accompanying unaudited condensed consolidated financial statements, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Website Development Costs The Company recognizes website development costs in accordance with ASC 350-50, “Accounting for Website Development Costs.” Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs may not always be available. Income Taxes We utilize ASC 740 “ Income Taxes The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Stock Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation – Stock Compensation We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Inventories The Company’s inventories represent finished goods, consist of products available for sale and are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share At October 31, 2020 and 2019, 4,748,292,511 potential shares (including 98,119,845 shares to be issued on the balance sheet) and 3,949,236,328 potential shares (including 81,786,511 shares to be issued on the balance sheet), respectively, were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of October 31, 2020 and April 30, 2020, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “ Accounting for Convertible Securities with Beneficial Conversion Features Reclassifications Certain reclassifications have been made to conform to prior periods’ data to the current presentation. These reclassifications had no effect on reported losses. Recent Accounting Pronouncements- In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (Topic 842) “ Leases Leases A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our unaudited condensed consolidated financial statements.

Going Concern Matters

Going Concern Matters	6 Months Ended
	Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Matters	NOTE B – GOING CONCERN MATTERS The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, the Company has incurred recurring losses and generated negative cash flows from operating activities since inception. As of October 31, 2020, the Company had an accumulated deficit of $65,082,461 and a working capital deficit (total current liabilities exceeded total current assets) of $12,452,072. The Company’s cash balance and revenues generated are not currently sufficient and cannot be projected to cover its operating expenses for the next twelve months from the filing date of this report. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. In order to improve the Company’s liquidity, the Company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing.

Notes Payable and Derivatives

Notes Payable and Derivatives	6 Months Ended
	Oct. 31, 2020
Debt Disclosure [Abstract]
Notes Payable and Derivatives	NOTE C – NOTES PAYABLE AND DERIVATIVES The Company has outstanding numerous notes payable to various parties. The notes bear interest at rates of 5% - 20% per year and are summarized as follows: Notes Payable October 31, 2020 April 30, 2020 Notes convertible at holder’s option $ 2,590,309 $ 2,590,309 Notes convertible at Company’s option 75,700 75,700 Non-convertible notes payable 2,372,646 2,276,315 Subtotal 5,038,655 4,942,324 Less debt discount - - $ 5,038,655 $ 4,942,324 Certain of the notes payable contain variable conversion rates and the conversion features are classified as derivative liabilities. The conversion prices are based on the market price of the Company’s common stock, at discounts of 30% - 48% to market value. At October 31, 2020, the Company has reserved 238,630,500 shares of its common stock for issuance upon the conversion of debentures. Amortization of debt discount for the three-month periods ended October 31, 2020 and 2019 was $0 and $6,825, respectively. The Company’s derivative financial instruments consist of embedded derivatives related to the outstanding short term Convertible Notes Payable. These embedded derivatives include certain conversion features indexed to the Company’s common stock. The accounting treatment of derivative financial instruments requires that the Company record the derivatives and related items at their fair values as of the inception date of the Convertible Notes Payable and at fair value as of each subsequent balance sheet date. In addition, under the provisions of Accounting Standards Codification subtopic 815-40, Derivatives and Hedging; Contracts in Entity’s Own Equity (“ASC 815-40”), as a result of entering into the Convertible Notes Payable, the Company is required to classify all other non-employee stock options and warrants as derivative liabilities and mark them to market at each reporting date. Any change in fair value inclusive of modifications of terms will be recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives is higher at the subsequent balance sheet date, the Company will record a non-operating, non-cash charge. If the fair value of the derivatives is lower at the subsequent balance sheet date, the Company will record non-operating, non-cash income. The change in fair value of the derivative liabilities at October 31, 2020 was calculated with the following average assumptions, using a Black-Scholes option pricing model are as follows: Significant Assumptions: Risk free interest rate Ranging from 0.11 to 0.2 % Expected stock price volatility Ranging from 135 to 273 % Expected dividend payout Expected life in years Ranging from 0.25 to 3.0 Years The change in fair value of the derivative liabilities of convertible notes outstanding at October 31, 2019 was calculated with the following average assumptions, using a Black-Scholes option-pricing model are as follows: Significant Assumptions: Risk free interest rate Ranging from 1.83% to 2.00 % Expected stock price volatility 118% to 187 % Expected dividend payout 0 % Expected life in years Ranging from 0.25 year to 2.0 years During the three months ended October 31, 2020 and 2019, the Company recorded a (loss) of $1,310,307 and a (loss) of $1,682,995, respectively, related to the change in value of the derivative liabilities. Changes in derivative liability during the three months ended October 31, 2020 and 2019 were: October 31, 2020 2019 Balance, beginning of year $ 2,802,125 $ 3,496,696 Derivative liability extinguished - - Derivative financial liability arising on the issuance of convertible notes and warrants 140,014 63,613 Fair value adjustments 1,310,307 1,682,995 Balance, end of period $ 4,252,446 $ 5,243,304

Loans Payable to Related Partie

Loans Payable to Related Parties	6 Months Ended
	Oct. 31, 2020
Related Party Transactions [Abstract]
Loans Payable to Related Parties	NOTE D – LOANS PAYABLE TO RELATED PARTIES As of October 31, 2020, and April 30, 2020, aggregated loans and notes payable, without demand and with no interest, to officers and directors were $450,500 and $432,403, respectively.

Equity Transactions

Equity Transactions	6 Months Ended
	Oct. 31, 2020
Equity [Abstract]
Equity Transactions	NOTE E EQUITY TRANSACTIONS The Company is authorized to issue 10,000,000 shares of preferred stock with $0.001 par value per share, of which 35,850 shares have been designated as Series A convertible preferred stock with a $100 stated value per share, 1,000 shares have been designated as Series B Preferred Stock with a $10,000 per share liquidation value, 200,000 shares have been designated as Series C Preferred Stock with a $10 per share liquidation value, and 2,000,000 shares have been designated as Series D Preferred Stock with a $1 per share liquidation value and 750,000,000 shares of common stock with $0.001 par value per share. The Company had 125 shares of Series A preferred stock issued and outstanding as of October 31, 2020 and April 30, 2020. The Company had no shares of Series B preferred stock issued and outstanding as of October 31, 2020 and April 30, 2020. The Company had 4,155,000 and 4,005,000 shares of Series C preferred stock issued and outstanding as of October 31, 2020 and April 30, 2020. The Company had 1,596,000 and 1,132,000 shares of Series D preferred stock issued and outstanding as of October 31, 2020 and April 30, 2020. The Company had 693,792,904 a Preferred Stock During the three months ended October 31, 2020, the Company: Sold 140 Units Series C Convertible Preferred stock for $70,000. Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.005 per share. Issued 311 Units Series D Convertible Preferred stock in settlement of $311,378 in accounts payable. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.01 per share. Issued 51 Units Series D Convertible Preferred stock upon conversion of $51,000 of the Company’s subsidiary’ preferred stock. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.01 per share. During the three months ended October 31, 2019, the Company: Sold 206 Units C Convertible Preferred stock for $103,000. Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.005 per share. Issued 92 Units C Convertible Preferred stock upon the conversion of $45,829 of notes payable and accrued interest thereon. Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.005 per share. Issued 125 Units D Convertible Preferred stock upon the conversion of $125,000 of the Company’s subsidiary’ preferred stock. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.01 per share. Common Stock During the three months ended October 31, 2020, the Company: Sold to two accredited investors 13,333,334 shares of common stock and two-year warrants, to purchase 6,666,667 shares of common stock at $0.004 per share, for $20,000. During the three months ended October 31, 2019, the Company: Accrued to be issued 1,000,000 shares of restricted common stock in consideration of the cancellation of $311,127 of accounts payable.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE F – FAIR VALUE MEASUREMENTS The Company follows the guidance established pursuant to ASC 820 which established a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 defines fair value as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes the following three levels of inputs that may be used: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs when there is little or no market data available, thereby requiring an entity to develop its own assumptions. The fair value hierarchy gives the lowest priority to Level 3 inputs. The table below summarizes the fair values of financial liabilities as of October 31, 2020: Fair Value at Fair Value Measurement Using October 31, 2020 Level 1 Level 2 Level 3 Derivative liabilities $ 4,252,446 - - $ 4,252,446 Fair values of financial liabilities as of April 30, 2020 are as follows: Fair Value at Fair Value Measurement Using April 30, 2020 Level 1 Level 2 Level 3 Derivative liabilities $ 2,802,125 - - $ 2,802,125 The following is a description of the valuation methodologies used for these items: Derivative liabilities The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC Topic 825 “ The Fair Value Option for Financial Issuances

Non-Cash Investing and Financin

Non-Cash Investing and Financing Information	6 Months Ended
	Oct. 31, 2020
Non-cash Investing And Financing Information
Non-Cash Investing and Financing Information	NOTE G – NON-CASH INVESTING AND FINANCING INFORMATION During the three months ended October 31, 2020, the Company: ● Issued 311 Units Series D Convertible Preferred stock in settlement of $311,378 in accounts payable. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two year Warrants to purchase one share of the Company’s common stock at $0.01 per share. ● Issued 51 Units Series D Convertible Preferred stock upon conversion of $51,000 of the Company’s subsidiary’ preferred stock. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.01 per share. During the three months ended October 31, 2019, the Company: ● Issued 92 Units C Convertible Preferred stock upon the conversion of $45,829 of notes payable and accrued interest thereon. Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.005 per share. ● Issued 125 Units D Convertible Preferred stock upon the conversion of $125,000 of the Company’s subsidiary’ preferred stock. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two year Warrants to purchase one share of the Company’s common stock at $0.01 per share. ● Accrued to be issued 1,000,000 shares of restricted common stock in consideration of the cancellation of $311,127 of accounts payable.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Oct. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE H – COMMITMENTS AND CONTINGENCIES Operating Lease Commitments Our executive offices are located in New York, NY. We have an agreement for use of office space at this location under a sub-lease which expired on October 31, 2019 and continues on a month-to-month basis thereafter. The monthly base rent is $5,100. Rent expense was $16,200 and $13,250 for the three-month periods ended October 31, 2020 and 2019, respectively. Litigation The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. Sparta can make no representations about the potential outcome of such proceedings. As of October 31, 2020, we were not a party to any material pending legal proceeding except as stated below. From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. The Company has received notices dated April 1, 2016, May 13, 2016 and July 22, 2016 from two lenders claiming defaults relating to conversion requests of $8,365 principal and $643 interest and $5,000 principal, with regard to notes in the total amounts of $55,125 and $27,500, respectively, which the Company has refused to process and believes it has defenses in that regard. The company believes these claims are contingent, unliquidated and disputed. There can be no assurance that the Company would prevail should litigation with regard to any of these requests occur. These liabilities have been recorded in the unaudited condensed consolidated financial statements. On September 22, 2016, a motion for summary judgment in lieu of complaint was filed in the Supreme Court of The State of New York County of Kings, against the Company by a lender for the amount of $102,170.82 in principal and interest; accrued and unpaid interest thereupon in the amount from the date of filing to entry of judgment herein; lender’s reasonable attorney’s fees, costs, and expenses; and any such other relief as the Court deems just and proper. Plaintiff’s motion for summary judgment in lieu of complaint was denied on May 5, 2017 . On October 26, 2019, a lender commenced an action in the Supreme Court of the State of New York in New York County alleging damages from unpaid principal and interest, attorney’s fees, costs, and expenses arising from a promissory note dated February 26, 2015 in the amount of $50,000.00. The case is presently in the discovery phase of the litigation. The Company believes the claim is contingent, unliquidated and disputed.

Subsequent Events

Subsequent Events	6 Months Ended
	Oct. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE I – SUBSEQUENT EVENTS Subsequent to October 31, 2020 the Company: Sold, to an accredited investor, 3,333,334 Shares of Common stock (and two-year warrants to purchase 1,666,667 shares of common stock at $0.004 per share) for $5,000. Sold, to an accredited investor, 10 Units of Series C convertible preferred stock for $10,000. Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.005 per share. On July 9, 2020, the Company filed with the Securities and Exchange Commission, a Schedule 14C Information Statement whereby a majority of the Company’s shareholders approved a 1 for 100 reverse stock split of the Company’s common shares outstanding. As of the date of this filing, FINRA (the Financial Industry Regulatory Authority) has yet to approve the reverse stock split.

Summary of Accounting Policies

Summary of Accounting Policies (Policies)	6 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Business	Business Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation serving three markets. Sparta is a technology company that develops, markets and manages business mobile application (mobile apps) for smartphones and tablets. The Company also owns and manages websites which sell on-demand motorcycle, recreational vehicle, power-sport vehicle and truck title history reports for consumers, retail dealers, auction houses, insurance companies and banks/finance companies. Notwithstanding our discontinuance of consumer loans and leases, since 2007, we have offered, on a pass through basis, an equipment-leasing finance product for local and state agencies throughout the country seeking an alternative and economical way to finance their essential equipment needs, including police motorcycles and cruisers, buses and EMS equipment. Our historic customers can be viewed at https://www.spartamunicipal.com/clients Our roots are in the Powersports industry and our original focus was providing consumer leasing and retail installment contracts as well as municipal financing to the powersports, recreational vehicle, and automobile industries. Presently, through our subsidiary, iMobile Solutions, Inc. (“IMS”), we offer mobile application development, sales, marketing and support, and Vehicle Title History Reports. Our mobile application (mobile app) offerings have broadened our base beyond vehicle dealers to a wide range of businesses including, but not limited to, racetracks, private clubs, country clubs, restaurants and grocery stores. Our clients can be seen at https://imobileapp.com/app-gallery/ The Company also designs, launches, maintains, and hosts websites for businesses. We provide specific, tailored action plans for our clients’ websites that include services such as eCommerce, CRM (Customer Relationship Management) development and integration, ordering system creation and integration, SEO (search engine optimization), social media marketing, and online reviews to improve their presence online. In addition, we offer text messaging services which are vital for businesses’ marketing, retention and loyalty strategies. Our text messaging platform allows our clients to easily manage, schedule, and analyze text message performance. Our vehicle history reports, which can be found on Kelly Blue Book, AutoTrader, AllState Insurance, as well as on various dealership websites, include Cyclechex (Motorcycle History Reports at www.cyclechex.com www.rvchecks.com www.carvinreport.com www.truckchex.com New World Health Brands, Inc. (NWHB) was formed in April 2019 as a subsidiary and new business line of Sparta Commercial Services, Inc. While anticipating, and with the passing of the 2018 Farm Bill, which resulted in the removal of hemp (CBD) from Schedule 1 of the Controlled Substances Act. Sparta’s management recognized a substantial potential business opportunity in the rapidly expanding Hemp-CBD (Cannabinol) market in the United States. During 2019-2020, management sourced, developed and tested 5 CBD product categories totaling 31 products, procured product packaging, labeling, implemented fulfillment and launched an on-line B to C website, www.newworldhealthcbd.co
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of October 31, 2020 and for the three month periods ended October 31, 2020 and 2019 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2020 as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission. The results of operations for the three months ended October 31, 2020 are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2020. The condensed consolidated balance sheet as of April 30, 2020 contained herein has been derived from the audited consolidated financial statements as of April 30, 2020, but do not include all disclosures required by the U.S. GAAP.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit.
Estimates	Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in United States of America which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the reported period. Accordingly, actual results could differ from those estimates. Included in these estimates are assumptions about collection of accounts receivable, useful life of property and equipment, beneficial conversion feature of convertible notes payable, deferred income tax asset valuation allowances, and valuation of derivative liabilities
Revenue Recognition	Revenue Recognition During the first quarter of 2018, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606), using the cumulative-effect method. The new standard requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption did not have an impact in our consolidated financial statements, other than the enhancement of our disclosures related to our revenue-generating activities. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions. Revenues from mobile app products and New World Health products are generally recognized upon delivery. Revenues from history reports are generally recognized upon delivery / download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery.
Cash Equivalents	Cash Equivalents For the purpose of the accompanying unaudited condensed consolidated financial statements, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
Website Development Costs	Website Development Costs The Company recognizes website development costs in accordance with ASC 350-50, “Accounting for Website Development Costs.”
Fair Value Measurements	Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs may not always be available.
Income Taxes	Income Taxes We utilize ASC 740 “ Income Taxes The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense.
Stock Based Compensation	Stock Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation – Stock Compensation We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.
Inventories	Inventories The Company’s inventories represent finished goods, consist of products available for sale and are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
Net Loss Per Share	Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share At October 31, 2020 and 2019, 4,748,292,511 potential shares (including 98,119,845 shares to be issued on the balance sheet) and 3,949,236,328 potential shares (including 81,786,511 shares to be issued on the balance sheet), respectively, were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.
Derivative Liabilities	Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of October 31, 2020 and April 30, 2020, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “ Accounting for Convertible Securities with Beneficial Conversion Features
Reclassifications	Reclassifications Certain reclassifications have been made to conform to prior periods’ data to the current presentation. These reclassifications had no effect on reported losses.
Recent Accounting Pronouncements	Recent Accounting Pronouncements- In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (Topic 842) “ Leases Leases A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our unaudited condensed consolidated financial statements.

Notes Payable and Derivatives (

Notes Payable and Derivatives (Tables)	6 Months Ended
	Oct. 31, 2020
Debt Disclosure [Abstract]
Schedule of Notes Payable	The Company has outstanding numerous notes payable to various parties. The notes bear interest at rates of 5% - 20% per year and are summarized as follows: Notes Payable October 31, 2020 April 30, 2020 Notes convertible at holder’s option $ 2,590,309 $ 2,590,309 Notes convertible at Company’s option 75,700 75,700 Non-convertible notes payable 2,372,646 2,276,315 Subtotal 5,038,655 4,942,324 Less debt discount - - $ 5,038,655 $ 4,942,324
Schedule of Derivative Liabilities Assumptions Using Black-Scholes Option	The change in fair value of the derivative liabilities at October 31, 2020 was calculated with the following average assumptions, using a Black-Scholes option pricing model are as follows: Significant Assumptions: Risk free interest rate Ranging from 0.11 to 0.2 % Expected stock price volatility Ranging from 135 to 273 % Expected dividend payout Expected life in years Ranging from 0.25 to 3.0 Years The change in fair value of the derivative liabilities of convertible notes outstanding at October 31, 2019 was calculated with the following average assumptions, using a Black-Scholes option-pricing model are as follows: Significant Assumptions: Risk free interest rate Ranging from 1.83% to 2.00 % Expected stock price volatility 118% to 187 % Expected dividend payout 0 % Expected life in years Ranging from 0.25 year to 2.0 years
Schedule of Changes in Derivative Liabilities	Changes in derivative liability during the three months ended October 31, 2020 and 2019 were: October 31, 2020 2019 Balance, beginning of year $ 2,802,125 $ 3,496,696 Derivative liability extinguished - - Derivative financial liability arising on the issuance of convertible notes and warrants 140,014 63,613 Fair value adjustments 1,310,307 1,682,995 Balance, end of period $ 4,252,446 $ 5,243,304

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Values of Financial Liabilities	The table below summarizes the fair values of financial liabilities as of October 31, 2020: Fair Value at Fair Value Measurement Using October 31, 2020 Level 1 Level 2 Level 3 Derivative liabilities $ 4,252,446 - - $ 4,252,446 Fair values of financial liabilities as of April 30, 2020 are as follows: Fair Value at Fair Value Measurement Using April 30, 2020 Level 1 Level 2 Level 3 Derivative liabilities $ 2,802,125 - - $ 2,802,125

Summary of Accounting Policie_2

Summary of Accounting Policies (Details Narrative) - shares	6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Antidilutive securities excluded from computation of earnings per share, amount	4,748,292,511	3,949,236,328
Shares to be Issued [Member]
Antidilutive securities excluded from computation of earnings per share, amount	98,119,845	81,786,511

Going Concern Matters (Details

Going Concern Matters (Details Narrative) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (65,082,461)	$ (62,702,339)
Working capital deficit	$ 12,452,072

Notes Payable and Derivatives_2

Notes Payable and Derivatives (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Amortization of debt discount		$ 6,825		$ 7,800
Loss on derivative liabilties	$ 1,310,307	$ 1,682,995
Issuance Upon Conversion of Debentures [Member]
Number of common stock reserved for conversion			238,630,500
Minimum [Member]
Debt instrument, interest rate	5.00%		5.00%
Common stock discount rate, percentage			30.00%
Maximum [Member]
Debt instrument, interest rate	20.00%		20.00%
Common stock discount rate, percentage			48.00%

Notes Payable and Derivatives -

Notes Payable and Derivatives - Schedule of Notes Payable (Details) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Subtotal	$ 5,038,655	$ 4,942,324
Less Debt discount
Total	5,038,655	4,942,324
Notes Convertible at Holder's Option [Member]
Subtotal	2,590,309	2,590,309
Notes Convertible at Company's Option [Member]
Subtotal	75,700	75,700
Non-Convertible Notes Payable [Member]
Subtotal	$ 2,372,646	$ 2,276,315

Notes Payable and Derivatives_3

Notes Payable and Derivatives - Schedule of Derivative Liabilities Assumptions Using Black-Scholes Option (Details)	6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Risk Free Interest Rate [Member] | Minimum [Member]
Derivative liability, measurement input, percentage	0.11	1.83
Risk Free Interest Rate [Member] | Maximum [Member]
Derivative liability, measurement input, percentage	0.2	2
Expected Stock Price Volatility [Member] | Minimum [Member]
Derivative liability, measurement input, percentage	135	118
Expected Stock Price Volatility [Member] | Maximum [Member]
Derivative liability, measurement input, percentage	273	187
Expected Dividend Payout [Member]
Derivative liability, measurement input, percentage	0	0
Expected Life in Years [Member] | Minimum [Member]
Derivative liability, measurement input, expected life	2 months 30 days	2 months 30 days
Expected Life in Years [Member] | Maximum [Member]
Derivative liability, measurement input, expected life	3 years	2 years

Notes Payable and Derivatives_4

Notes Payable and Derivatives - Schedule of Changes in Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Debt Disclosure [Abstract]
Balance, beginning of year	$ 2,802,125	$ 3,496,696
Derivative liability extinguished
Derivative financial liability arising on the issuance of convertible notes and warrants	140,014	63,613
Fair value adjustments	1,310,307	1,682,995
Balance, end of year	$ 4,252,466	$ 5,243,304

Loans Payable to Related Part_2

Loans Payable to Related Parties (Details Narrative) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Related Party Transactions [Abstract]
Loans payable to officers and directors	$ 450,500	$ 432,403

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Apr. 30, 2020
Preferred stock, shares authorized	10,000,000		10,000,000
Preferred stock, par value	$ 0.001		$ 0.001
Common stock, shares authorized	750,000,000		750,000,000
Common stock, par value	$ 0.001		$ 0.001
Common stock, shares issued	693,792,904		627,092,904
Common stock, shares outstanding	693,792,904		627,092,904
Common stock to be issued	121,452,845		84,786,511
Common Stock [Member] | Accredited Investors [Member]
Number of stocks sold during period	13,333,334
Sale of stock	$ 20,000
Warrant [Member] | Accredited Investors [Member]
Number of warrants to purchase common shares	6,666,667
Common stock, price per share	$ 0.004
Consideration Cancellation of Accounts Payable [Member]
Number of restricted common stock		1,000,000
Number of restricted common stock, value		$ 311,127
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	35,850		35,850
Preferred stock, par value	$ 100		$ 100
Preferred stock, shares outstanding	125		125
Preferred stock, shares issued	125		125
Series B Preferred Stock [Member]
Preferred stock, shares authorized	1,000		1,000
Preferred stock, liquidation preference	$ 10,000		$ 10,000
Preferred stock, shares outstanding
Preferred stock, shares issued
Series C Preferred Stock [Member]
Preferred stock, shares authorized	200,000		200,000
Preferred stock, par value	$ 10		$ 10
Preferred stock, shares outstanding	4,155,000		4,005,000
Preferred stock, shares issued	4,155,000		4,005,000
Series D Preferred Stock [Member]
Preferred stock, shares authorized	200,000		2,000,000
Preferred stock, liquidation preference	$ 1		$ 1
Preferred stock, shares outstanding	1,596,000		1,132,000
Preferred stock, shares issued	1,596,000		1,132,000
Series C Convertible Preferred Stock [Member]
Number of stocks sold during period	140	206
Sale of stock	$ 70,000	$ 103,000
Convertible preferred stock, terms of conversion	Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company's common stock)	Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company's common stock)
Number of warrants to purchase common shares	150	150
Warrants term	2 years	2 years
Common stock, price per share	$ 0.005	$ 0.005
Series C Convertible Preferred Stock [Member] | Conversion of Notes Payable and Accrued Liabilities [Member]
Convertible preferred stock, terms of conversion		Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company's common stock)
Number of warrants to purchase common shares		150
Warrants term		2 years
Common stock, price per share		$ 0.005
Number of shares issued during period		$ 45,829
Number of shares issued during period, shares		92
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, terms of conversion	Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company's common stock)	Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company's common stock)
Number of warrants to purchase common shares	150	150
Warrants term	2 years	2 years
Common stock, price per share	$ 0.01	$ 0.01
Number of shares issued during period	$ 51,000	$ 125,000
Number of shares issued during period, shares	51	125
Series D Convertible Preferred Stock [Member] | Settlement of Accounts Payable [Member]
Convertible preferred stock, terms of conversion	Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company's common stock)
Number of warrants to purchase common shares	150
Warrants term	2 years
Common stock, price per share	$ 0.01
Number of shares issued during period	$ 311,378
Number of shares issued during period, shares	311

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Values of Financial Liabilities (Details) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Derivative liabilities	$ 4,252,446	$ 2,802,125
Fair Value, Inputs, Level 1 [Member]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member]
Derivative liabilities	$ 4,252,446	$ 2,802,125

Non-Cash Financial Information

Non-Cash Financial Information (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Restricted Common Stock [Member]
Number of restricted common stock		1,000,000
Cancellation of accounts payable		$ 311,127
Series D Convertible Preferred Stock [Member]
Shares issued on conversion of debt, shares	51
Note principal and accrued interest	$ 51,000
Debt conversion description	Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company's common stock) and 150 two year Warrants to purchase one share of the Company's common stock at $0.01 per share.
Conversion of stock, shares converted	400
Warrant exercise price	$ 0.01
Series D Convertible Preferred Stock [Member] | Settlement of Accounts Payable [Member]
Shares issued on conversion of debt, shares	311
Note principal and accrued interest	$ 311,378
Debt conversion description	Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company's common stock) and 150 two year Warrants to purchase one share of the Company's common stock at $0.01 per share.
Conversion of stock, shares converted	400
Warrant exercise price	$ 0.01
Series C Convertible Preferred Stock [Member]
Shares issued on conversion of debt, shares		92
Note principal and accrued interest		$ 45,829
Debt conversion description		Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company's common stock) and 150 two year Warrants to purchase one share of the Company's common stock at $0.005 per share.
Conversion of stock, shares converted		300
Warrant exercise price		$ 0.005
Series C Convertible Preferred Stock [Member] | Conversion of Notes Payable and Accrued Liabilities [Member]
Shares issued on conversion of debt, shares		125
Note principal and accrued interest		$ 125,000
Debt conversion description		Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company's common stock) and 150 two year Warrants to purchase one share of the Company's common stock at $0.01 per share.
Conversion of stock, shares converted		400
Warrant exercise price		$ 0.01

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Sep. 22, 2016	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Feb. 26, 2015
Promissory Note [Member]
Aggregate note amount					$ 50,000
New York County Kings [Member]
Loss on contingent	$ 102,171
Lender One [Member]
Debt principal amount		$ 8,365		$ 8,365
Debt interest		643		643
Aggregate note amount		55,125		55,125
Lender Two [Member]
Debt principal amount		5,000		5,000
Aggregate note amount		27,500		$ 27,500
Executive Office Space [Member]
Lease expiring date				Oct. 31, 2019
Rent expense		$ 16,200	$ 13,250	$ 5,100

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jul. 09, 2020	Dec. 21, 2020	Jul. 31, 2020	Jul. 31, 2019
Shares issued on conversion of debt, value				$ 45,829
Reverse stock split	1 for 100 reverse split
Subsequent Event [Member] | Accredited Investor [Member]
Number of shares issued during the period, shares		3,333,334
Debt instrument, term		2 years
Warrants to purchase shares		1,666,667
Share price		$ 0.004
Number of shares issued during the period		$ 5,000
Shares issued on conversion of debt, shares		10
Shares issued on conversion of debt, value		$ 10,000
Debt conversion description		Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company's common stock) and 150 two year Warrants to purchase one share of the Company's common stock at $0.005 per share.
Conversion of stock, shares converted		300
Warrant exercise price		$ 0.005